October 22, 2017 - MYR Pharma presents positive interim results in MYR 202 clinical trial
July - September, 2017 – Several review articles highlight Myrcludex B as a strong contender in the treatment of Hepatitis D and B:
- Kaufmann, S.H., Dorhoi, A., Hotchkiss, R.S. and Bartenschlager, R., 2018. Host-directed therapies for bacterial and viral infections. Nature Reviews Drug Discovery, 17(1), p.35.
- Lempp, F.A. and Urban, S., 2017. Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. Viruses, 9(7), p.172.
- Rizzetto, M., 2017. Investigational drugs in development for hepatitis D. Expert opinion on investigational drugs, 26(9), pp.999-1005.
May 25, 2016 – Initiation of MYR 203